BioRestorative Therapies Inc (BRTX) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, the financial performance shows significant revenue decline, and there are no strong trading signals or positive trends to support an immediate purchase. While the company has made progress in its intellectual property and clinical trials, these are long-term catalysts that may not yield immediate returns. A 'hold' action is recommended until clearer positive trends emerge.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 0.253 and support at 0.203.

Positive Catalysts

The company has received a patent approval in Australia for its ThermoStem® technology, enhancing its position in obesity and metabolic disease treatments. The ongoing Phase 2 clinical trial for BRTX-100 targeting chronic lower back pain may provide future growth opportunities.

Neutral/Negative Catalysts

Gross margin also fell by -88.70%, indicating operational challenges. Additionally, there are no significant trading trends from hedge funds or insiders, and technical indicators remain bearish.

Financial Performance

In 2025/Q3, revenue dropped by -94.95% YoY to $11,800. Net income improved to -$3,038,277 (up 178.38% YoY), and EPS increased to -0.33 (up 153.85% YoY). However, gross margin dropped significantly to 10.42%, down -88.70% YoY, reflecting operational inefficiencies.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast BRTX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.228

Low

Averages

High